Small interfering RNA targeting receptor for advanced glycation end products suppresses the generation of proinflammatory cytokines

Wang,Xiao‑Wei; Li,Wei‑Dong; Xia,Jin‑Rong; Li,Zhan; Cai,Xiao‑Gang

doi:10.3892/etm.2015.2569

Small interfering RNA targeting receptor for advanced glycation end products suppresses the generation of proinflammatory cytokines

Authors:
- Xiao‑Wei Wang
- Wei‑Dong Li
- Jin‑Rong Xia
- Zhan Li
- Xiao‑Gang Cai
View Affiliations

Affiliations: Department of Gastroenterology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, P.R. China, Department of Gastroenterology, Langxi Chinese Medicine Hospital, Langxi, Anhui 242100, P.R. China
Published online on: June 11, 2015 https://doi.org/10.3892/etm.2015.2569
Pages: 584-590

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of receptor for advanced glycation end products (RAGE)‑specific small interfering (si)RNA on the generation of proinflammatory cytokines in primary rat hepatic stellate cells (HSCs) and hepatic fibrotic (HF) rats. The RAGE‑specific siRNA expression vector pAKD‑GR126 was constructed, and then transfected into primary rat HSCs. Reverse transcription‑quantitative polymerase chain reaction and western blot analyses were conducted to determine the mRNA and protein expression levels, respectively, of RAGE, tumor necrosis factor (TNF)‑α and interleukin (IL)‑6 in the primary HSCs. In addition, a CCl4‑induced Sprague Dawley (SD) rat model of hepatic fibrosis was established, and pAKD‑GR126 was injected into the SD rats via the tail vein. Serum TNF‑α and IL‑6 concentrations were determined using radioimmunoassay. The mRNA and protein expression levels of RAGE (mRNA, F=7.791; protein, F=36.513), TNF‑α (mRNA, F=474.568; protein, F=123.500) and IL‑6 (mRNA, F=203.463; protein, F=320.555) in the pAKD‑GR126‑transfected primary HSCs were significantly reduced compared with those in the control and pAKD‑NC groups (P<0.05). Serum TNF‑α and IL‑6 levels in the low‑, medium‑ and high‑dose pAKD‑GR126 treatment groups were reduced compared with those in the fibrotic model group (TNF‑α, F=416.397; IL‑6, F=1,716.659; P<0.05). In summary, the RAGE‑specific siRNA was able to effectively suppress the generation of the proinflammatory cytokines TNF‑α and IL‑6 in primary rat HSCs and HF rats.

View Figures

View References

1	Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, Lopez R, Christine CK, Feldstein AE and Alkhouri N: The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci. 60:1440–1447. 2015. View Article : Google Scholar : PubMed/NCBI
2	Roy S, Benz F, Luedde T and Roderburg C: The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis. Hepatobiliary Surg Nutr. 4:24–33. 2015.PubMed/NCBI
3	Hegab Z, Gibbons S, Neyses L and Mamas MA: Role of advanced glycation end products in cardiovascular disease. World J Cardiol. 4:90–102. 2012. View Article : Google Scholar : PubMed/NCBI
4	Barlovic DP, Soro-Paavonen A and Jandeleit-Dahm KA: RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond). 121:43–55. 2011. View Article : Google Scholar : PubMed/NCBI
5	Lee UE and Friedman SL: Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 25:195–206. 2011. View Article : Google Scholar : PubMed/NCBI
6	Lohwasser C, Neureiter D, Popov Y, Bauer M and Schuppan D: Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol. 15:5789–5798. 2009. View Article : Google Scholar : PubMed/NCBI
7	Guimarães EL, Empsen C, Geerts A and van Grunsven LA: Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol. 52:389–397. 2010. View Article : Google Scholar : PubMed/NCBI
8	Xia JR, Liu NF and Zhu NX: Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats. Int J Mol Sci. 9:638–661. 2008. View Article : Google Scholar : PubMed/NCBI
9	Lin J, Tang Y, Kang Q, Feng Y and Chen A: Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress. Br J Pharmacol. 166:2212–2227. 2012. View Article : Google Scholar : PubMed/NCBI
10	Goodwin M, Herath C, Jia Z, Leung C, Coughlan MT, Forbes J and Angus P: Advanced glycation end products augment experimental hepatic fibrosis. J Gastroenterol Hepatol. 28:369–376. 2013. View Article : Google Scholar : PubMed/NCBI
11	Hsu WH, Lee BH, Hsu YW and Pan TM: Peroxisome proliferator-activated receptor-γ activators monascin and rosiglitazone attenuate carboxymethyllysine-induced fibrosis in hepatic stellate cells through regulating the oxidative stress pathway but independent of the receptor for advanced glycation end products signaling. J Agric Food Chem. 61:6873–6879. 2013. View Article : Google Scholar : PubMed/NCBI
12	Scheuer PJ: Classification of chronic viral hepatitis: A need for reassessment. J Hepatol. 13:372–374. 1991. View Article : Google Scholar : PubMed/NCBI
13	Hyogo H and Yamagishi S: Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des. 14:969–972. 2008. View Article : Google Scholar : PubMed/NCBI
14	Pusterla T, Nèmeth J, Stein I, Wiechert L, Knigin D, Marhenke S, Longerich T, Kumar V, Arnold B, Vogel A, et al: Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology. 58:363–373. 2013. View Article : Google Scholar : PubMed/NCBI
15	Watson AM, Gray SP, Jiaze L, Soro-Paavonen A, Wong B, Cooper ME, Bierhaus A, Pickering R, Tikellis C, Tsorotes D, et al: Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes. 61:2105–2113. 2012. View Article : Google Scholar : PubMed/NCBI
16	Fehrenbach H, Weiskirchen R, Kasper M and Gressner AM: Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology. 34:943–952. 2001. View Article : Google Scholar : PubMed/NCBI
17	Zhang SC, Zheng YH, Yu PP, Min TH, Yu FX, Ye C, Xie YK and Zhang QY: Lentiviral vector-mediated down-regulation of IL-17A receptor in hepatic stellate cells results in decreased secretion of IL-6. World J Gastroenterol. 18:3696–3704. 2012. View Article : Google Scholar : PubMed/NCBI
18	Lee BH, Hsu WH, Hsu YW and Pan TM: Suppression of dimerumic acid on hepatic fibrosis caused from carboxymethyl-lysine (CML) by attenuating oxidative stress depends on Nrf2 activation in hepatic stellate cells (HSCs). Food Chem Toxicol. 62:413–419. 2013. View Article : Google Scholar : PubMed/NCBI
19	Tang Y and Chen A: Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Invest. 94:503–516. 2014. View Article : Google Scholar : PubMed/NCBI
20	Klironomos S, Notas G, Sfakianaki O, Kiagiadaki F, Xidakis C and Kouroumalis E: Octreotide modulates the effects on fibrosis of TNF-α, TGF-β and PDGF in activated rat hepatic stellate cells. Regul Pept. 188:5–12. 2014. View Article : Google Scholar : PubMed/NCBI
21	Ming-Ju H, Yih-Shou H, Tzy-Yen C and Hui-Ling C: Hepatitis C virus E2 protein induce reactive oxygen species (ROS)-related fibrogenesis in the HSC-T6 hepatic stellate cell line. J Cell Biochem. 112:233–243. 2011. View Article : Google Scholar : PubMed/NCBI
22	Radwan MI, Pasha HF, Mohamed RH, Hussien HI and El-Khshab MN: Influence of transforming growth factor-β1 and tumor necrosis factor-α genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine. 60:271–276. 2012. View Article : Google Scholar : PubMed/NCBI
23	Yang YY, Liu RS, Lee PC, et al: Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat. Liver Int. 34:521–534. 2014. View Article : Google Scholar : PubMed/NCBI